Centrosome size is controlled by a limiting component mechanism in which a fixed quantity of precursor protein is divided up among however many centrosomes are present. This simple scheme explains size control and scaling of centrosomes relative to cell volume.
The mechanisms that determine organelle size remain almost entirely unknown, but a new study, published in this issue of Current Biology, on centrosome size regulation during Caenorhabditis elegans embryogenesis has now provided evidence for an extremely simple mechanism that may apply to a wide range of other organelles [1] . Several theoretical mechanisms for organelle size control have been described -for example, molecular rulers, which represent protein molecules whose physical size determines the size of an assembling structure. Rulers have been shown to control length in bacterial injection needles [2] and bacteriophage tails [3] . Ruler mechanisms require a way to align the ruler relative to the assembling structure, and to read out the location of the assembling structure relative to the end of the ruler. Other schemes, such as feedback loops that measure and adjust organelle size, are even more complex.
Wouldn't it be simpler if there was a way to use the components of the structure itself as a way to control its size? Perhaps the simplest way to control the size of a structure is a limiting component mechanism, in which a cell produces a fixed quantity of precursor, which is then assembled into the final structure, such that the structure assembles until the precursor component is entirely exhausted from the cytoplasm. The quantity of precursor component produced by the cell would thus directly determine the size of the structure. If precursor concentration was the same in all cells at the time that assembly starts, then larger cells would form proportionally larger structures since they would contain more of the limiting component ( Figure 1 ). This type of model can thus account for both size control and scaling of organelle size with cell size. The limiting component model is conceptually appealing, but how do we know if it applies in any given situation?
One way to test for a limiting component mechanism is to ask how the size of the structure varies as a function of the number of copies of the structure within one cell. If a cell makes M molecules of the size-limiting precursor, which must then be distributed among N copies of the organelle, then the average number of precursor molecules per copy is M/N, hence the size of the structure should be proportional to 1/N. Such a dependence means that, if a cell has two copies of the structure, the structures would be half as big as they would be if the cell had just one. In a cell with three copies, they would each be one-third as large. Alternatively, if you add up the volume of all the copies of the structure, the total volume should be constant, independent of the number of copies. Another hallmark of a limiting component system is that the growth rate of the structure should gradually slow down and reach a plateau as the limiting component is exhausted from the cytoplasm. Structures that cease growth abruptly when they reach a particular size would thus not be consistent with this type of model and one would therefore have to look for other types of mechanisms, such as rulers, to explain their size control.
This general idea of a limiting component model was first proposed by Kuchka and Jarvik [4] for flagellar length control in the green alga Chlamydomonas reinhardtii, a model system in which it was already known that reduced expression of precursor proteins resulted in decreased length [5] . Measurements in mutants that change the number of flagella per cell revealed that flagellar length decreased in cells with more flagella, but did not decrease as steeply with increasing number as the limiting component model would predict [6] . A simple limiting component model was thus ruled out in that system, and indeed there has not been a clear-cut example of a limiting component model for organelle size control until now.
In the new study, Decker and co-workers [1] examined the size of centrosomes in developing C. elegans embryos, in which all protein is provided maternally, hence the total quantity of centrosome precursor protein is fixed during the early divisions. What they found was that, as early divisions proceeded, producing more and more centrosomes in the embryo, centrosomes were smaller and smaller but the total summed volume of the centrosomes was indeed constant, as predicted by the limiting component model.
When individual centrosomes were examined and compared to the size of the cells that contained them, it was found that centrosome volume was linearly proportional to cell volume. This also fits with a limiting component model since the volume of the whole embryo is constant, and precursor is presumably distributed during cell division proportionally to the volume of the daughter cells, hence larger cells obtain a proportionally larger fraction of the initial quantity of precursor.
Decker et al. [1] further confirmed that centrosome size was truly cell-size dependent and not a consequence of differences in cell fate that normally correlate with difference in cell size, by the elegant use of an embryo-size-altering mutant in which all cells are smaller. Comparing cells of identical cell fate between normal and small embryos, it was found that cell size correlated with centrosome size while cell fate did not [1] .
Centrosome growth rate also varied with cell size, suggesting that centrosomes in cells with more precursor grew at a faster rate. This may seem odd since molecular assembly rates typically depend on concentration of precursor, not total quantity in the cell. Larger cells should have the same precursor concentration as smaller cells, and hence should grow at the same rate, at least initially. However, as the centrosomes grow, they deplete precursors from the cytoplasm. For any unit increase in centrosome size, the same quantity of monomers is consumed from the cytoplasm in each cell. The resulting change in precursor concentration will be greater in smaller cells. Hence, at any particular size of the centrosome, its instantaneous growth rate should be lower in smaller cells, as reported. Overall, the slowing in growth rate as centrosomes become larger and reach a plateau is consistent with the gradual exhaustion of a limiting component from the cytoplasm.
The results of Decker et al. [1] underscore the degree of mechanistic insight that can be obtained by careful quantitative analysis. The authors also went one step beyond and identified at least one gene, spd-2, whose expression level appears to control centrosome size and growth rate. Spd-2 is a key protein involved in recruiting pericentriolar material onto centrioles to form a centrosome [7, 8] . In Drosophila, centrosome size is at least in part determined by the rate of recruitment of Centrosomin, a Spd-2-interacting protein [9] . Decker et al. [1] further provide evidence that Spd-2 controls centrosome assembly rate by recruiting Polo-like kinase 1 (PLK1) to the centrosome.
Is Spd-2 the 'limiting component' of the limiting component model? Probably not. The term limiting component implies a structural building block depleted from the cytoplasm during growth, and whose final exhaustion from the cytoplasm determines the point at which growth ceases. But Spd-2 protein is not a structural building block of the centrosome. Rather, Spd-2 apparently recruits PLK1, which then directs further assembly, implying that Spd-2 is not itself the building block but instead facilitates utilization of the actual centrosome building blocks. Increased quantities of Spd-2 presumably allow precursor to be utilized at lower concentrations, thus allowing centrosomes to grow larger when more Spd-2 is present.
It is known that centrosome size affects mitotic spindle length [10] .
Interestingly, mitotic spindle length was shown to scale with cell size in early embryos of Xenopus [11] such that smaller cells produce shorter spindles, at least once the size of the cells drops below some critical size scale. Is this scaling of spindle length a by-product of centrosome size scaling? It would be interesting to know whether modulation of Spd-2 levels could alter the scaling relationship between cell size and spindle length in that situation.
The limiting precursor model solves the size control problem by creating a new problem -how to maintain a constant total precursor pool. This is not an issue in early embryos where all centrosome growth depends on the initial precursor pool provided by the mother when the egg is laid. But will the model still work in postembryonic cells that have active transcription and translation? What would keep the total precursor quantity constant in such a case? Ironically, the simple-sounding limiting component model may require sophisticated biological regulatory mechanisms to control the synthesis of the limiting component. Cell Migration: PKA and RhoA Set the Pace A new study shows that protein kinase A (PKA) activity establishes a signaling loop that governs protrusion-retraction cycles in migrating cells. PKA activity near the leading edge of protrusions phosphorylates RhoA and inhibits its activity via increased association with RhoGDI.
Karen A. Newell-Litwa and Alan Rick Horwitz* Oscillatory cycles of membrane protrusion and retraction at the leading edge are a common feature of cell migration. Protrusions are membrane extensions characterized by dynamic nascent adhesions and actin polymerization, while retractions are contractile events characterized by the presence of elongating adhesions associated with actomyosin bundles (Figure 1 ) [1] [2] [3] [4] [5] . Alternation between these two phases establishes an oscillatory wave [1, 5] .
Despite extensive documentation of protrusion-retraction cycles in a variety of migratory cells from Dictyostelium to mammalian fibroblasts [1, 4] , the mechanism that determines their periodicity is still unclear, and may vary among cell types. In general, the proposed mechanisms postulate that actomyosin reorganization at the lamellipodia-lamella interface establishes protrusion-retraction cycles [1, 5] . The balance between actin polymerization within the lamellipodium and actin de-polymerization and bundling near the lamellipodia-lamella interface likely results from separation of activities that nucleate actin, such as Arp2/3, from those that depolymerize, bundle and contract actin, like cofilin and myosin II [1, 4, 6] . In mammalian cells, myosin IIA and myosin light chain kinase move in waves coincident with retrograde actin flow [4, 5] . Presumably this phosphorylates and activates myosin II, which bundles and contracts actin filaments within the lamellum [4] .
Inhibition of myosin activity alters the oscillatory cycles [4, 5] .
Rho GTPases are signaling convergence points that regulate the localized activities involved in actin dynamics and organization [7] . Guanine nucleotide exchange factors (GEFs) activate Rho GTPases, leading to membrane association, while GTPase-activating proteins (GAPs) stimulate GTPase activity, leading to Rho GTPase inhibition [7] . GDP dissociation inhibitors (GDIs) bind to inactive Rho, sequestering it in the cytosol away from the activating GEFs at the membrane [7] . In a highly coordinated spatial and temporal activity profile at the leading edge, RhoA activity peaks with protrusion formation, followed by Cdc42 and Rac activation, which likely initiates the next protrusion cycle [8] .
In spite of the evidence that coordinated RhoGTPase activity drives diverse actomyosin assemblies to produce protrusion-retraction cycles, an 'oscillator' that synchronizes these dynamic processes is now described in a recent study. Tkachenko et al. [9] identified an oscillatory loop between protein kinase A (PKA) activity and RhoA-Rho-GDI association that underlies protrusion-retraction cycles (Figures 1 and 2 ). Using fluorescence resonance energy transfer (FRET) biosensors that report local PKA and RhoA activity, they correlated molecular activity with cell edge movement, thereby determining the precise spatial and temporal activities of these various components. They also demonstrated that disruption of these oscillatory components, using inhibitors and mutants, altered the frequency, duration, magnitude, and propagation of the protrusion-retraction cycle.
Previous work identified PKA as an integrin-associated kinase that is active at the leading edge and contributes to cell migration [10, 11] . This positioning of PKA activity at the leading edge coupled with its ability to regulate actomyosin assembly through RhoGTPase activity [12] led Tkachenko et al. [9] to investigate whether PKA serves as the oscillator that establishes protrusion-retraction cycles. Using the cell leading edge as a spatial and temporal reference point, they observed that PKA activity correlated with protrusion formation. Inhibition of PKA activity disrupted protrusion-retraction cycles, resulting Figure 1 . PKA establishes a protrusionretraction oscillation by phosphorylating RhoA. Protrusions drive actin polymerization (blue lines) and adhesion formation (pink circles). Both Rho and PKA are active (*) in protrusions. However, PKA phosphorylates RhoA at the leading edge and removes it from the membrane by promoting the association between RhoA and RhoGDI, leading to sequestration of RhoA in the cytosol. Retraction formation is characterized by actomyosin bundles (blue bundles) and elongating adhesions (pink ovals).
